<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269891</url>
  </required_header>
  <id_info>
    <org_study_id>14NMHB</org_study_id>
    <nct_id>NCT02269891</nct_id>
  </id_info>
  <brief_title>A Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women</brief_title>
  <acronym>14NMHB</acronym>
  <official_title>A Randomized Double-Blind, Placebo-Controlled, Parallel Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Synergize Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotropics Malaysia Berhad</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Synergize Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness of an herbal combination product
      called Nu Femme, on menopausal symptoms in peri-menopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of hot flashes</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Assessed based on hot flash symptoms score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of joint pain</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Assessed based on joint pain symptoms score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of hot flashes</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Assessed based on hot flash symptoms score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of hot flashes</measure>
    <time_frame>Week 12 to week 24</time_frame>
    <description>Assessed based on hot flash symptoms score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of joint pain</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Assessed based on joint pain symptoms score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of joint pain</measure>
    <time_frame>Week 12 to week 24</time_frame>
    <description>Assessed based on joint pain symptoms score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>Baseline to weeks 3, 6, 12 and 24</time_frame>
    <description>Assessed using the Menopause Rating Scale (MRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menopause specific quality of life</measure>
    <time_frame>Baseline to weeks 3, 6, 12 and 24</time_frame>
    <description>Assessed using the Menopause Specific Quality of Life questionnaire (MENQOL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hormone concentrations</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Estradiol-17b, FSH, LH, total testosterone and free testosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Lipid Profile</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Total cholesterol, HDL-C, LDL-C and triglycerides</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bone markers</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>NTX and BSALP</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood safety parameters</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>CBC, electrolytes (Na K CL), glucose, creatinine, BUN, AST, ALT, GGT, bilirubin, Ca, albumin</description>
  </other_outcome>
  <other_outcome>
    <measure>Pap smear</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Histological analysis for abnormal cells</description>
  </other_outcome>
  <other_outcome>
    <measure>Pelvic ultrasound</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>To determine changes in endometrial thickness</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Baseline to week 12</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Menopausal Symptoms</condition>
  <arm_group>
    <arm_group_label>Nu Femme</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two capsules (500mg total) taken once daily in the morning after breakfast for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two capsules taken once daily in the morning after breakfast for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nu Femme</intervention_name>
    <description>Combination product of Labisia pumila and Eurycoma longifolia extracts</description>
    <arm_group_label>Nu Femme</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female of any race between the ages of 40 and 55 years (inclusive)

          -  Experiencing perimenopause (irregular menstrual cycles (&gt;3 months) or cessation of
             menstrual period for at least 3 months within the last 12 months) OR women in
             menopause (cessation of menstrual period for at least 12 months).

          -  Peri-menopausal women must have an endometrial stripe &lt; 8 mm by ultrasound at
             screening and menopausal women must have an endometrial stripe &lt; 5 mm. Not required
             for subjects without an intact uterus.

          -  Women with an intact cervix must have a pap smear that is normal within 12 months of
             screening.

          -  Experiences menopausal transition symptoms such as hot flushes, sweating, sleep
             disturbance, migraine, anxiety, vaginal dryness and sexual problems.

          -  Minimum of 4 hot flashes per day or 28 per week

          -  Total scores of Menopause Rating Scale â‰¥17 indicating the menopausal symptoms are
             moderate or severe

          -  TSH screening to exclude undiagnosed hyperthyroidism

          -  Willingness and ability to give written informed consent and willingness and ability
             to understand, to participate and to comply with the study requirements.

        Exclusion Criteria:

          -  Women with a positive mammogram

          -  Significant cardiac history including uncontrolled hypertension (defined as untreated
             systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 100 mmHg) or
             current diagnosis of any major diseases of the cardiovascular, hepatic, renal,
             gastrointestinal, pulmonary or endocrine systems

          -  Uncontrolled hyperlipidemia

          -  History or current diagnosis of breast cancer or breast cancer in an identical twin,
             or any cancer (except non-melanomatous skin cancer) diagnosed less than 5 years prior
             to randomization. Subjects with other cancers in full remission more than 5 years
             after diagnosis are acceptable with the exceptions of breast cancer or genital organ
             cancer (e.g., cervical cancer, uterine cancer, endometrial cancer, or ovarian cancer)

          -  Uncontrolled diabetes (Type I or Type II)

          -  Uncontrolled and/or untreated thyroid disorder

          -  History or current diagnosis of any major diseases of the cardiovascular, hepatic,
             renal, gastrointestinal, pulmonary or endocrine systems

          -  History or current diagnosis of autoimmune conditions, immunodeficiency or
             gynaecological disease

          -  Clinically significant mental depression that is not well-controlled in the opinion of
             the investigator

          -  Subject has undergone major surgery within the past one year prior to the
             randomization visit, except cholecystectomy, and appendectomy

          -  Subject smokes more than 15 cigarettes a day

          -  History of alcohol or drug abuse within the past year

          -  Subject has demonstrated non-compliance with treatment while enrolled in other
             experimental protocols to which the Investigator has knowledge

          -  Subject has a mental disability or significant mental illness, legal incapacity or
             limited legal capacity or any other lack of fitness, in the Investigator's opinion, to
             preclude subject's participation in or to complete the study

          -  History or findings of undiagnosed abnormal vaginal bleeding within the previous two
             years prior to the randomization visit, including conditions that, in the
             Investigator's opinion are likely to be the source of unpredictable vaginal bleeding
             (i.e. leiomyoma or endometrial polyps)

          -  Subject has uterine fibroids (&gt; 2cm) or endometriosis. This assessment will be based
             on the size of the uterus of each participant and will be assessed by the Qualified
             Investigator

          -  Pregnant, breastfeeding, or planning to become pregnant during the course of the trial

          -  Positive urine pregnancy test result

          -  Polycystic ovary syndrome (PCOS)

          -  History of abnormal Pap smear

          -  Significant abnormal liver function as defined as AST and/or ALT &gt; 2 x the upper limit
             of normal (ULN), and/or bilirubin &gt; 2 x the ULN

          -  eGFR &lt;60

          -  Bleeding disorders or anaemia of any etiology defined as haemoglobin â‰¤ 110 g/L

          -  Subject has taken any of the following medications in the time periods specified prior
             to the screening visit and during the study

        Sex hormones:

        Vaginal rings and vaginal creams, ointments or gels 1 week Transdermal or topical 4 weeks
        DHEA within 24 weeks Natural supplements advertised to have hormonal effects within 4 weeks
        Oral within 4 weeks Intrauterine progestin implants within 8 weeks Progestin implants and
        estrogen alone injections within 12 weeks Injected progestin and estrogen or androgen
        implants or pellets within 24 weeks

        Gonadotropin-releasing hormone (GnRH) agonists within 24 weeks

        Selective Estrogen Receptor Modulators (SERMs) within 4 weeks

        Glucocorticoids - Chronic high dose (â‰¥ 7.5 mg prednisone per day or equivalent) for the
        past 12 weeks. Exceptions: Chronic low dose corticosteroid use (&lt; 7.5 mg prednisone per
        day, or equivalent) is permitted provided the subject has been stabilized on a dose for at
        least 12 weeks prior to randomization and maintains the current dose and dosing regimen
        during the study. Acute topical, inhaled, or oral (e.g. dose packs) use is not exclusionary
        and will be permitted during the course of the study.

        Antidepressant and/or antianxiety medications within 4 weeks unless a chronic stable dose
        has been maintained for greater than 12 weeks. Subject must maintain current dose and
        dosing regimen during the study. Use of Effexor (Venlafaxine HCl) within 4 weeks is
        exclusionary. Use of Dixarit (Clonidine HCl) within 2 weeks is exclusionary.

        Thyroid or anti-epileptic medications within 12 weeks unless a chronic stable dose has been
        maintained for greater than 12 weeks prior to randomization. Subjects must maintain current
        dose and dosing regimen during the study

        Use of Prostaglandins within 4 weeks

        Other investigational study medications within 4 weeks

        Current use of propranolol

        Current use of an intrauterine device (IUD)

        Use of natural health products, such as primrose oil, black cohosh, soy products, other
        than vitamin and/or mineral supplements within 4 weeks

          -  Known allergy or hypersensitivity to study product ingredients

          -  Subjects on a weight reduction program or a medically supervised diet.

          -  Unexplained weight loss or weight gain of more than 5 kg in the month prior to
             randomization

          -  Any other condition which in the Investigator's opinion may adversely affect the
             subject's ability to complete the study or its measures or which may pose significant
             risk to the subject
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Pelipyagina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Synergize Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mal Evans, PhD</last_name>
    <phone>(519) 438-9374</phone>
    <phone_ext>239</phone_ext>
    <email>mevans@kgksynergize.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Manna Research - Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6J 1S3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mal Evans, PhD</last_name>
      <phone>(519) 438-9374</phone>
      <phone_ext>239</phone_ext>
      <email>mevans@kgksynergize.com</email>
    </contact>
    <investigator>
      <last_name>Tetyana Pelipyagina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manna Research - Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Navneet Arora</last_name>
      <phone>416-740-2895</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manna Research - Quebec</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6W 0M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manna Research - Montreal</name>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>January 6, 2017</last_update_submitted>
  <last_update_submitted_qc>January 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menopausal symptoms</keyword>
  <keyword>Peri-menopause</keyword>
  <keyword>Nu Femme</keyword>
  <keyword>Labisia pumila</keyword>
  <keyword>Eurycoma longifolia</keyword>
  <keyword>Hot flash</keyword>
  <keyword>Joint pain</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

